Novartis
Basel, Switzerland
Completed
NCT Number: NCT05870657
Adherence and Persistence to Inclisiran Among Early Users in Germany
The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering therapies (LLT) in a real-world setting in Germany. Analysis was carried out using the IQVIA™ LRx database.
Completed
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Study subjects ≥18 years old who were prescribed an inclisiran dose.
Exclusion criteria
None
Treatment and study plan
Primary outcomes
-
Number and percentage of patients with at least 5 months of potential follow-up who were prescribed a second dose of inclisiran
Time frame: 8 months
-
Percentage of patients who were prescribed a second dose of inclisiran between 1 and 6 months after prescription of first dose
Time frame: 8 months
-
Median time between first and second prescribed doses
Time frame: 8 months
Secondary outcomes
-
Age and gender characteristics
Time frame: 6 months
-
Age and gender distribution
Time frame: 6 months
-
Prescriber specialty distribution for patients
Time frame: 6 months
Sponsors and collaborators
Lead sponsor
Novartis Pharmaceuticals
Industry
Registry information
Important dates
- Study start
- 2022
- Primary completion
- 2022
- Study completion
- 2022
- First posted
- May 23, 2023
- Registry last updated
- May 23, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.